Anti-emetics in development

Bibliography

• ASHP COMMISSION ON THERAPEUTICS: ASHP therapeutic guidelines on the management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am. Health-Syst. Phann. (1999) 56:729–764.
   PubMed Web of Science ®Google Scholar
• GRALLA RJ, OSOBA D, KRIS MG et al: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J. Clin. Oncol (1999) 17:2971–2994.
   PubMed Web of Science ®Google Scholar
• •A typical evidence-based practice guideline for anti-emetic therapy in patients receiving chemotherapy.
   Google Scholar
• ANTIEMETIC SUBCOMMITTEE OF THE MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER (MASCC): Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann. °flea. (1998) 9:811–819.
   Google Scholar
• DOMINO KB, ANDERSON EA, POLLISAR NL, POSNER KL: Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anesth. Analg. (1999) 88:1370–1379.
   PubMed Web of Science ®Google Scholar
• LOEWEN PS, MARRA CA, ZED RI: 5-HT3receptor antagonists versus traditional agents for the prophylaxis of postoperative nausea and vomiting. Can. Anaesthesia (2000) 47(10):1008–1018.
   PubMed Web of Science ®Google Scholar
• ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. .1 Clin. °flea. (1993) 11:2396–2404.
   Google Scholar
• HERON JF, GOEDHALS L, JORDAAN JP et al: Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann. Oncol (1994) 5:579–584.
   PubMed Web of Science ®Google Scholar
• THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Ondansetronversus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. I Clin. Oncol (1997) 15:124–130.
   PubMed Web of Science ®Google Scholar
• CARPENTER DO, BRIGGS DB, STROMINGER N: Peptide induced emesis in dogs. Behav. Brain Res. (1984) 11:277–281.
   PubMed Web of Science ®Google Scholar
• ANDREWS PLR, BHANDARI P: Resinferatwdn, an ultrapotent capsaicin analogue, has antiemetic properties in the ferret. Nerurophapnacology (1993) 32:799–806.
   PubMed Web of Science ®Google Scholar
• ••A seminal "proof of concept" papersupporting the role of neurokinins in MEV.
   Google Scholar
• TATTERSALL FD, RYCROFT W, FRANCIS B et al.: Tachykinin NKi receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neurophannacology (1996) 35:1121–1129.
   PubMed Web of Science ®Google Scholar
• DIEMUNSCH P, LAURENT GRELOT: Potential of substance P antagonists as antiemetics. Drugs (2000) 60(3):533–546.
   PubMed Web of Science ®Google Scholar
• RUPNIAK NM, TATTERSALL FD, WILLIAMS AR et al.: In vitro and in vivo predictors of the antiemetic efficacy of tachykinin NKi receptor antagonists. Ear. J. Pharmacol. (1997) 326:201–209.
   PubMed Web of Science ®Google Scholar
• WATSON JW, GONSALVES SF, FOSSA AA et al.: The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br. J. Pharmacol (1995) 115:84–94.
   PubMed Web of Science ®Google Scholar
• FUKUDA H, KOGA T, FURUKAWA N et al.: The tachykinin NK1 receptor antagonist GR 205171 prevents vagal stimulation induced retching but not neuronal transmission from emetic vagal afferents to solitary nucleus neurons in dogs. Brain Res. (1998) 802:221–231.
   PubMed Web of Science ®Google Scholar
• RUDD JA, NGAN MP, WAI MK: Inhibition of emesis by tachykinin NK1 receptor antagonists in Suncus murinus (house musk shrew). Ear: Pharmacol (1999) 366:243–252.
   PubMed Web of Science ®Google Scholar
• ZAMAN S, WOODS AJ, WATSON JW, REYNOLDS DJ, ANDREWS PL. The effect of the NK1 receptor antagonist CP-99,994 on emesis and c-fos protein induction by loperamide in the ferret. Neuropharmacology (2000) 39(2):316–323.
   Google Scholar
• FUKADA H, KOGA T, FURUKAWA N, NAKAMURA E, SHIROSHITA Y. The tachykinin NK1 receptor antagonist GR205171 abolishes the retching activity of neurons comprising the central pattern generator for vomiting in dogs. Neurosci. Res. (1999) 33(1):25–32.
   Google Scholar
• MINAMI M, ENDO T, KIKUCHI K et al.: Antiemetic effects of sendide, a peptide tachykinin NK1 receptor antagonist, in the ferret. Eur. Pharmacol (1998) 363:49–55.
   PubMed Web of Science ®Google Scholar
• KRIS MG, RADFORD J, PIZZO BA et al: Control of emesis following cisplatin by CP-122,721, a selective NK1 receptor antagonist. J. Natl. Cancer Inst. (1997) 89:817–818.
   PubMed Web of Science ®Google Scholar
• NAVARI PM, REINHARDT RR, GRALLA RJ et al.: Reduction of cisplatin-induced emesis by a selective neurokinin- 1-receptor antagonist. N Engl. J. Med. (1999) 340:190–195.
   PubMed Web of Science ®Google Scholar
• CAMPOS D, PEREIRA JR, REINHARDTRR et al.: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-896, in combination with granisetron and dexamethasone or with dexamethasone alone." Clin. Oncol (2001) 19:1759-1767. Well-conducted clinical trial.
   Google Scholar
• COCQUYT V, VANBELLE S, REINHARDT RR et al.: Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754-030, with ondansetron for the prevention of cisplatin-induced emesis. Ear: J. Cancer (2001) 37:835–842.
   Google Scholar
• •Well-conducted clinical trial.
   Google Scholar
• HESKETH PJ, GRALLA RJ, WEBB RT: Randomized Phase II study of the neurokinin 1 receptor antagonist CJ- 11,974 in the control of cisplatin-induced emesis. .1 Cliii. Oncol (1999) 17:338–343.
   PubMed Web of Science ®Google Scholar
• •Well-conducted clinical trial.
   Google Scholar
• EVANGELISTA S: Ezlopitant Pfizer. Carr. Opin. Investig. Drugs (2001) 2:1441–1443.
   PubMedGoogle Scholar
• GESZTESI Z, SCUDERI PE, WHITE PF et al.: Substance P (neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology (2000) 93:931–937.
   PubMed Web of Science ®Google Scholar
• •Well-conducted clinical trial.
   Google Scholar
• DIEMUNSCH P, SCHOEFFLER P, BRYSSINE B et al.: Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br. J. Anaesth. (1999) 82:274–276.
   PubMed Web of Science ®Google Scholar
• •Well-conducted clinical trial.
   Google Scholar
• REID K, PALMER JL, WRIGHT RJ al:Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br. I Clin. Pharmacol (2000) 50:61–64.
   PubMed Web of Science ®Google Scholar
• GOLDSCHMIDT H, SALWENDER H, EGERER G, KEMPE R, VOIGT T: Comparison of oral itasetron with oral ondansetron: Results of a double- blind, active-controlled Phase II study in chemotherapy-naïve patients receiving moderately emetogenic chemotherapy. Anti- Cancer Drugs (1997) 8:436–444.
   PubMed Web of Science ®Google Scholar
• TANG J, D'ANGELO R, WHITE PF, SCUDERI PE: The efficacy of RS-25259, a long-acting selective 5-HT3 receptor antagonist, for preventing postoperative nausea and vomiting after hysterectomy procedures. Anesth. Analg (1998) 87:462–467.
   PubMed Web of Science ®Google Scholar
• HERRSTEDT J: Antiemetic research: a lookto the future. Support Cancer Care (1998) 6:8–12.
   PubMed Web of Science ®Google Scholar
• DE VRY J: 5-HT(1A) receptor agonists: Recent developments and controversial issues. Psychopharmacology (1995) 121:1–26.
   PubMed Web of Science ®Google Scholar
• OKADA F, TORII Y, SAITO H, MATSUKI N: Antiemetic effects of serotonergic HT(1A)-receptor agonists in Suncus murinus. Japanese I. Pharmacol (1994) 64:109–114.
   PubMedGoogle Scholar
• WOLFF MC, LEANDER JD: Effects of a 5-HT(1A) receptor agonist on acute and delayed cyclophosphamide-induced vomiting. Eur. Pharmacol. (1997) 340:217–220.
   PubMed Web of Science ®Google Scholar
• OKADA F, SAITO H, MATSUKI N: Blockade of motion- and cisplatin-induced emesis by a 5-HT2 receptor antagonist in Suncus murinus. Br. J. Pharmacol. (1995) 114:931–934.
   PubMed Web of Science ®Google Scholar
• SIMONEAU II, HAMZA MS, MATA HP et al.: The cannabinoid agonist WINS 5,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology (2001) 94:882–887.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA T, YOSHIDA N, OKA M: The broad spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3, and 5-HT3 receptors antagonist. Br. J. Pharmacol. (2001) 133:253–260.
   PubMed Web of Science ®Google Scholar